key: cord-1046963-oj1i1f8w authors: Bularca, E.; Monte‐Serrano, J.; Villagrasa‐Boli, P.; Lapeña‐Casado, A.; de‐la‐Fuente, S. title: Reply to “COVID vaccine–induced lichen planus on areas previously affected by vitiligo” date: 2022-02-21 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.18001 sha: a4a5d9fa82ca7d0cb8b9a6bc6ba7f28592a4f493 doc_id: 1046963 cord_uid: oj1i1f8w nan Since the beginning of the immunization programs, COVID vaccine-induced rashes have been documented in several cases. 1 We report the case of a 29-year-old woman with vitiligo on her hands that appeared more than 10 years ago. One week after administration of Pfizer-BioNTech COVID-19 vaccine, she developed LP-suggestive lesions on depigmented areas, which progressed after the second vaccine administration, involving skin areas not previously affected by vitiligo. At the time of consultation, erythematous, polygonal papules were seen on the dorsum of the hands, wrists, eyelids, submammary region, and lower extremities. Oral mucosa examination revealed reticular white marking and white plaques (Fig. 1) . The skin biopsy of abdominal lesions confirmed LP diagnosis, showing acanthosis and basal cell degeneration with civatte bodies and band-like dermal lymphocytic infiltrate. Blood tests including biochemical and hematological parameters were normal. Antinuclear antibodies (ANAs) and serologies for hepatitis B, C, and HIV were negative. Topical clobetasol propionate and systemic prednisone were prescribed, with partial resolution of the lesions. Subsequently, treatment with methotrexate 10 mg a week was started with progressive improvement. Considering the clinical and histopathological findings, and the onset and worsening of the skin eruption in relation to the COVID-19 vaccine, diagnosis of vaccine-induced LP was rendered. The exact pathogenesis of the association of LP and COVID-19 vaccinations is still unknown. A recent review of this association found 33 cases of LP arising after various vaccinations, including hepatitis B, influenza, and herpes zoster vaccines. 2 It is known that LP dermatitis is induced by CD8+ cytotoxic T cells and maintained by the release of IL-2, TNF-a, and IFN-c by CD4+ lymphocytes. All COVID-19 vaccines induce a T-cell driven response with B-cell activation, antibody production, and increased levels of cytokines, including IL-2, TNF-a, and IFN-c. 3, 4 In addition to the case described by Piccolo et al, there are four other published reports of oral or cutaneous LP in association with COVID-19 vaccination (Table 1) . [5] [6] [7] [8] [9] Here, we report a new case of LP triggered by COVID-19 vaccination with development of cutaneous lesions, initially on vitiliginous depigmented areas, and subsequently on normal skin and oral mucosa. In our case, because of the clinical exacerbation following the administration of the second dose of the vaccine, immunomodulatory treatment with methotrexate was required. We encourage dermatologists to screen patients presenting with recent onset of dermatologic disease or sudden worsening of preexisting conditions to inquire about COVID-19 vaccination to increase awareness in this particular area. This article received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The patients in this manuscript have given written informed consent to publication of their case details. We read with interest the paper of Yu Olisova et al. recently published on JEADV 1 about different dermatoses caused by face mask wearing during the COVID-19 pandemic. The authors warned on the localization of lesions, typically observed only under the mask on cheeks, chin, and nasal bridge. We present a case series observed in our centre, which adds some hints of discussion. Ten patients (four females and six males, aged 32-74 years) presented with psoriasis on retro-auricular area induced by COVID mask. Eight of them were affected by psoriasis and received biological treatment, including etanercept (2/8 pts), adalimumab (2/8 pts), brodalumab (1/8 pt), ustekinumab (1/8 pt), secukinumab (1/8 pt) and guselkumab (1/8 pt). The patients had good control of the psoriasis with 5/8 patients with complete remission, while 3/8 patients presented a minimal residual Eruptive pseudoangiomatosis Acute hemangiomalike lesions associated with ECHO viral infections Eruptive pseudoangiomatosis in an adult Eruptive pseudoangiomatosis in adults with immune system disorders: a report of two cases An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US Eruptive pseudoangiomatosis and SARS-CoV-2 (COVID-19) infection COVID-19 vaccination-induced rash: does the choice of vaccine matter? Lichen planus and lichenoid drug eruption after vaccination Oral lichen planus: an update on its pathogenesis Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S) New-onset cutaneous lichen planus triggered by COVID-19 vaccination Lichen planus arising after COVID-19 vaccination Development of oral lichen planus after COVID-19 vaccination -a rare case report COVID vaccine-induced lichen planus on areas previously affected by vitiligo Dermatoses caused by face mask wearing during the COVID-19 pandemic We thank the patient for granting permission as written informed consent to publish the case details and for clinical photography